Beclomethasone (Beclometasone)

Before prescribing inhalants, the patient should be instructed on the rules for their use, ensuring the most complete entry of the drug into the right areas of the lungs. The development of oral candidiasis is most likely in patients with a high level of precipitating antibodies in the blood against the fungus Candida, which indicates an earlier transferred fungal infection. After inhalation, rinse the mouth and throat with water. For the treatment of candidiasis, antifungal agents of local action can be used while continuing therapy with Beclomethasone.

If patients take GCS inside, then Beclomethasone is appointed on the background of receiving the previous dose of SCS, while patients should be in a relatively stable state. After about 1-2 weeks, the daily dose of oral glucocorticosteroids is gradually reduced. The dose reduction scheme depends on the duration of the previous therapy and on the initial dose of GCS. Regular use of inhaled glucocorticosteroids allows in most cases to cancel oral GCS (patients who need to take no more than 15 mg of prednisolone can be fully switched to inhalation therapy). In the first months after the transition, the patient's condition should be carefully monitored until his pituitary-adrenal system is restored sufficiently to provide adequate response to stressful situations (eg, trauma, surgery or infection).

When transferring patients from receiving systemic GCS to inhalation therapy, allergic reactions (for example, allergic rhinitis, eczema), which were previously suppressed by systemic drugs, may appear.

Patients with a reduced function of the adrenal cortex, transferred to inhalation treatment, should have a stock of GCS and always carry a warning card, which should indicate that they need additional systemic appointment of SCS in stressful situations (after a stressful situation, the dose of GCS can be again reduce). A sudden and progressive worsening of asthma symptoms is a potentially dangerous condition, not uncommon for the patient's life, and requires an increase in the dose of GCS. An indirect indicator of the ineffectiveness of therapy is the more frequent, than before use (3-2-adrenergic stimulants of short action.

Beclomethasone dipropionate for inhalations is not intended for relief of seizures, but for regular daily use. To stop seizures apply (3-2-adrenergic stimulants of short action (for example, salbutamol).In case of severe exacerbation of bronchial asthma or inadequate efficacy of the therapy, the dose of inhaled beclomethasone dipropionate should be increased and, if necessary, a systemic SCS and an antibiotic should be prescribed for the development of infection.

With the development of paradoxical bronchospasm should immediately stop using Beclomethasone, assess the patient's condition, examination and, if necessary, prescribe therapy with other medications. With long-term use of any inhaled glucocorticosteroids, especially at high doses, systemic effects can be noted (see "Side Effects"), but the likelihood of their development is significantly lower than when ingesting GCS inside. Therefore, it is especially important that, when the therapeutic effect is achieved, the dose of inhaled glucocorticosteroids is reduced to the lowest effective dose controlling the course of the disease. At a dose of 1500 μg / day, the drug in most patients does not cause significant suppression of adrenal function. In connection with a possible adrenal insufficiency, one should be extra careful and regularly monitor the indices of the function of the adrenal cortex when transferring patients taking SCS inward to beclomethasone.